Seven monoclonal antibodies that react specifically with amyloid beta peptides can be used as the research tools for Alzheimer’s disease (AD) research.
Researchers at UC Irvine’s MIND Institute developed a set of seven hybridoma cell lines that produce monoclonal antibodies specifically against Aβ1-42. Antibodies 124-12, 02-5, 04-3, 55-7, and 56-2 recognize the epitope that resides within the N-terminal amino acids 1-15 of Aβ1-42 peptide. They were tested on western blotting and immunohistochemistry during the development. Antibody 55-7 was also tested as a capture antibody for ELISA. Antibody1313 was made specifically against the Aβx-40 c-terminal CVGGVV peptide. It shows high specificity and reactivity for Aβx-40 and was tested for western blotting, immunohistochemical staining, and ELISA detection antibody purposes. Antibody 1313 also shows significant therapeutically effect in treatment of APP/Tg2576 mouse model of AD. The final monoclonal antibody 2B4 was made reacting to the epitope CVGGVVIA of the c-terminus of Aβx-42 peptide. It has similar research applications as antibody 1313. The above antibodies are used for detection of amyloid beta peptides and valuable for AD research.